Search

Your search keyword '"Rosenkilde, Mette M."' showing total 32 results
Start Over Author "Rosenkilde, Mette M." Publisher wiley
32 results on '"Rosenkilde, Mette M."'

5. Loss of Adgra3 causes obstructive azoospermia with high penetrance in male mice

Author

Nybo, Maja L., primary, Kvam, Jone M., additional, Nielsen, John E., additional, Frederiksen, Hanne, additional, Spiess, Katja, additional, Jensen, Kristian H. R., additional, Gadgaard, Sarina, additional, Walser, Anna L. S., additional, Thomsen, Jesper S., additional, Cowin, Pamela, additional, Juul, Anders, additional, Jensen, Martin Blomberg, additional, and Rosenkilde, Mette M., additional

Published
2023
Full Text
View/download PDF

6. Acute concomitant glucose‐dependent insulinotropic polypeptide receptor antagonism during glucagon‐like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity

Author

Stensen, Signe, primary, Krogh, Liva L., additional, Sparre‐Ulrich, Alexander H., additional, Dela, Flemming, additional, Hartmann, Bolette, additional, Vilsbøll, Tina, additional, Holst, Jens J., additional, Rosenkilde, Mette M., additional, Christensen, Mikkel B., additional, Gasbjerg, Lærke S., additional, and Knop, Filip K., additional

Published
2022
Full Text
View/download PDF

7. Author response for 'Acute concomitant glucose-dependent insulinotropic polypeptide receptor antagonism during glucagon-like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity'

Author

null Stensen, Signe, null Krogh, Liva L., null Sparre-Ulrich, Alexander H., null Dela, Flemming, null Hartmann, Bolette, null Vilsboll, Tina, null Holst, Jens J., null Rosenkilde, Mette M., null Christensen, Mikkel B., null Gasbjerg, Laerke S., and null Knop, Filip K.

Published
2022

8. Novel agonist and antagonist radioligands for the GLP‐2 receptor. Useful tools for studies of basic GLP‐2 receptor pharmacology

Author

Gadgaard, Sarina, primary, Velden, Wijnand J. C., additional, Schiellerup, Sine P., additional, Hunt, Jenna Elizabeth, additional, Gabe, Maria B. N., additional, Windeløv, Johanne Agerlin, additional, Boer, Geke Aline, additional, Kissow, Hannelouise, additional, Ørskov, Cathrine, additional, Holst, Jens J., additional, Hartmann, Bolette, additional, and Rosenkilde, Mette M., additional

Published
2022
Full Text
View/download PDF

11. Dose‐dependent efficacy of the glucose‐dependent insulinotropic polypeptide (GIP) receptor antagonist GIP(3‐30)NH2 on GIP actions in humans

Author

Gasbjerg, Lærke Smidt, primary, Bari, Emilie J., additional, Stensen, Signe, additional, Hoe, Bjørn, additional, Lanng, Amalie R., additional, Mathiesen, David S., additional, Christensen, Mikkel B., additional, Hartmann, Bolette, additional, Holst, Jens J., additional, Rosenkilde, Mette M., additional, and Knop, Filip Krag, additional

Published
2020
Full Text
View/download PDF

12. Enteroendocrine K Cells Exert Complementary Effects to Control Bone Quality and Mass in Mice

Author

Gobron, Benoît, primary, Bouvard, Béatrice, additional, Vyavahare, Sagar, additional, Blom, Liv VV, additional, Pedersen, Kristian K, additional, Windeløv, Johanne A, additional, Boer, Geke A, additional, Harada, Norio, additional, Zhang, Sheng, additional, Shimazu‐Kuwahara, Satoko, additional, Wice, Burton, additional, Inagaki, Nobuya, additional, Legrand, Erick, additional, Flatt, Peter R, additional, Chappard, Daniel, additional, Hartmann, Bolette, additional, Holst, Jens J, additional, Rosenkilde, Mette M, additional, Irwin, Nigel, additional, and Mabilleau, Guillaume, additional

Published
2020
Full Text
View/download PDF

13. Cover Image, Volume 1456, Issue 1

Author

Spiess, Katja, primary, Bagger, Sofie O., additional, Torz, Lola J., additional, Jensen, Kristian H. R., additional, Walser, Anna L., additional, Kvam, Jone M., additional, Møgelmose, Ann‐Sofie K., additional, Daugvilaite, Viktorija, additional, Junnila, Riia K., additional, Hjortø, Gertrud M., additional, and Rosenkilde, Mette M., additional

Published
2019
Full Text
View/download PDF

14. Arrestin‐independent constitutive endocytosis of GPR125/ADGRA3

Author

Spiess, Katja, primary, Bagger, Sofie O., additional, Torz, Lola J., additional, Jensen, Kristian H. R., additional, Walser, Anna L., additional, Kvam, Jone M., additional, Møgelmose, Ann‐Sofie K., additional, Daugvilaite, Viktorija, additional, Junnila, Riia K., additional, Hjortø, Gertrud M., additional, and Rosenkilde, Mette M., additional

Published
2019
Full Text
View/download PDF

30. Advancing the field of viroporins-Structure, function and pharmacology: IUPHAR Review 39.

Author

Devantier K, Kjær VMS, Griffin S, Kragelund BB, and Rosenkilde MM

Subjects
Animals, Humans, Antiviral Agents pharmacology, Antiviral Agents chemistry, Viroporin Proteins chemistry
Abstract

Viroporins possess important potential as antiviral targets due to their critical roles during virus life cycles, spanning from virus entry to egress. Although the antiviral amantadine targets the M2 viroporin of influenza A virus, successful progression of other viroporin inhibitors into clinical use remains challenging. These challenges relate in varying proportions to a lack of reliable full-length 3D-structures, difficulties in functionally characterising individual viroporins, and absence of verifiable direct binding between inhibitor and viroporin. This review offers perspectives to help overcome these challenges. We provide a comprehensive overview of the viroporin family, including their structural and functional features, highlighting the moldability of their energy landscapes and actions. To advance the field, we suggest a list of best practices to aspire towards unambiguous viroporin identification and characterisation, along with considerations of potential pitfalls. Finally, we present current and future scenarios of, and prospects for, viroporin targeting drugs., (© 2024 The Author(s). British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.)

Published
2024
Full Text
View/download PDF

31. Progress on the development of Class A GPCR-biased ligands.

Author

Morales P, Scharf MM, Bermudez M, Egyed A, Franco R, Hansen OK, Jagerovic N, Jakubík J, Keserű GM, Kiss DJ, Kozielewicz P, Larsen O, Majellaro M, Mallo-Abreu A, Navarro G, Prieto-Díaz R, Rosenkilde MM, Sotelo E, Stark H, Werner T, and Wingler LM

Abstract

Class A G protein-coupled receptors (GPCRs) continue to garner interest for their essential roles in cell signalling and their importance as drug targets. Although numerous drugs in the clinic target these receptors, over 60% GPCRs remain unexploited. Moreover, the adverse effects triggered by the available unbiased GPCR modulators, limit their use and therapeutic value. In this context, the elucidation of biased signalling has opened up new pharmacological avenues holding promise for safer therapeutics. Functionally selective ligands favour receptor conformations facilitating the recruitment of specific effectors and the modulation of the associated pathways. This review surveys the current drug discovery landscape of GPCR-biased modulators with a focus on recent advances. Understanding the biological effects of this preferential coupling is at different stages depending on the Class A GPCR family. Therefore, with a focus on individual GPCR families, we present a compilation of the functionally selective modulators reported over the past few years. In doing so, we dissect their therapeutic relevance, molecular determinants and potential clinical applications., (© 2024 The Author(s). British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.)

Published
2024
Full Text
View/download PDF

32. Pharmacokinetics of high-dose intravenous melatonin in humans.

Author

Andersen LP, Werner MU, Rosenkilde MM, Fenger AQ, Petersen MC, Rosenberg J, and Gögenur I

Subjects
Adult, Cross-Over Studies, Dose-Response Relationship, Drug, Healthy Volunteers, Humans, Injections, Intravenous, Male, Melatonin adverse effects, Melatonin blood, Reaction Time drug effects, Young Adult, Melatonin administration & dosage, Melatonin pharmacokinetics
Abstract

This crossover study investigated the pharmacokinetics and adverse effects of high-dose intravenous melatonin. Volunteers participated in 3 identical study sessions, receiving an intravenous bolus of 10 mg melatonin, 100 mg melatonin, and placebo. Blood samples were collected at baseline and 0, 60, 120, 180, 240, 300, 360, and 420 minutes after the bolus. Quantitative determination of plasma melatonin concentrations was performed using a radioimmunoassay technique. Pharmacokinetic parameters were estimated by a compartmental pharmacokinetic analysis. Adverse effects included assessments of sedation and registration of other symptoms. Sedation, evaluated as simple reaction times, was measured at baseline and 120, 180, 300, and 420 minutes after the bolus. Twelve male volunteers completed the study. Median (IQR) Cmax after the bolus injections of 10 mg and 100 mg of melatonin were 221,500.0 (185,637.5-326,175.0) pg/mL and 1,251,500.0 (864,375.0-1,770,500.0) pg/mL, respectively; mean (SD) t1/2 was 42.3 (5.6) minutes and 46.2 (6.2) minutes; mean (SD) Vd was 1.6 (0.9) L/kg and 2.0 (0.8) L/kg; mean (SD) CL was 0.0253 (0.0096) L/min · kg and 0.0300 (0.0120) L/min · kg; and median (IQR) AUC0- ∞ , 8,997,633.0 (6,071,696.2-11,602,811.9) pg · min/mL and 54,685,979.4 (36,028,638.6-105,779,612.0) pg · min/mL. High-dose intravenous melatonin did not induce sedation, evaluated as simple reaction times. No adverse effects were reported in the study., (© 2015, The American College of Clinical Pharmacology.)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results